rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IMVT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Immunovant director Atul Pande sells $108,000 in stock
      Nov 13Investing.comIMVT
      Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
      Nov 11Yahoo FinanceIMVT
      Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
      Nov 11Yahoo FinanceIMVT
      Immunovant (IMVT) Q2 2027 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 10The Globe and MailIMVT
      Immunovant Stock What Changed After Arthritis Trial Success
      Nov 9Yahoo FinanceIMVT
      Why Is Immunovant Stock Soaring Today? - Immunovant (NASDAQ:IMVT)
      Nov 9BenzingaIMVT
      What Immunovant (IMVT) Said on Its Q2 Earnings Call
      Nov 9Yahoo FinanceIMVTROIV
      Why is Immunovant stock surging today?
      Nov 9Investing.comIMVT
      Immunovant surges 10% on trial results, earnings beat
      Nov 9Investing.comIMVT
      S&P 500 Futures Up in Premarket Trading; Immunovant, Roivant Sciences Lead
      Nov 9Barron'sIMVT
      Immunovant CFO Tiago Girao sells $188,271 in shares
      Oct 31Investing.comIMVT
      Immunovant CTO Jay Stout sells $75,099 in shares
      Oct 24Investing.comIMVT
      Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
      Oct 21MorningstarIMVT
      Immunovant (IMVT) Stock Looks Stretched On Book Value Alone
      Oct 20Yahoo FinanceIMVT
      Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive Threats
      Oct 20Seeking AlphaIMVT
      Immunovant Q1 2027 Earnings Call: Complete Transcript - Immunovant (NASDAQ:IMVT)

      Immunovant (NASDAQ:IMVT) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial

      Oct 14BenzingaIMVT
      Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
      Oct 12MorningstarIMVT
      Immunovant CTO Jay Stout sells $122,116 in shares
      Oct 10Investing.comIMVT
      Immunovant chief legal officer Van Tuyl sells $42,543 in stock
      Oct 9Investing.comIMVT
      Immunovant COO Melanie Gloria sells shares worth $71,846
      Oct 9Investing.comIMVT
      Immunovant CEO Eric Venker sells $119,589 in shares
      Oct 6Investing.comIMVT
      Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next

      Immunovant recently reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, where the drug did not achieve statistical significance on the primary CLASI-A endpoint at Week 12, leading the company to halt development for this indication. Despite observing numerical trends favoring IMVT-1402 and better responses in patients with deeper IgG reductions, Immunovant concluded that the combination of these data and a competitive treatment...

      Sep 30Yahoo FinanceIMVT
      Sjogren’s Syndrome Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036 – DelveInsight | Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherap
      Sep 29BarchartIMVT
      Immunovant (IMVT) Just Gave Investors Something To Think About

      Immunovant (IMVT) just told the market that its proof-of-concept Phase 2b trial for IMVT-1402 in cutaneous lupus erythematosus missed the primary efficacy goal, and the program in this indication is being discontinued. The mixed trial outcome lands at a sensitive moment for Immunovant. The share price is US$33.49 after a 1-day share price return of 0.57%, yet the 7-day share price return is down 9.92% and the 30-day share price return is down 18.71%. This hints that recent traders have been...

      Sep 29Yahoo FinanceIMVT
      Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

      Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program. Gline said Roivant recently received a

      Sep 28Yahoo FinanceIMVTROIV
      Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case

      We all have bad days. Immunovant, Inc. (NASDAQ:IMVT) had its latest bad day on September 23 after a clinical-trial setback, sending the shares lower. The company reported that its Phase 2b proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve the primary endpoint. The study failed to show a statistically significant difference […]

      Sep 27Yahoo FinanceIMVT
      Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
      Sep 25MorningstarIMVT
      Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS)

      Tipranks Press Release.

      Sep 24The Globe and MailIMVT
      IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down

      Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.

      Sep 24Yahoo FinanceIMVT
      Lilly’s latest China drug deal; Immunovant’s setback in lupus

      Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

      Sep 24Yahoo FinanceIMVTLLY
      Immunovant stock rating maintained at Buy by H.C. Wainwright
      Sep 24Investing.comIMVT
      Roivant reports top-line data from IMVT-1402 CLE trial
      Sep 24Yahoo FinanceIMVTROIV
      Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
      Sep 23Barron'sIMVT
      Immunovant stock falls after lupus drug trial misses goal
      Sep 23Investing.comIMVT
      Why is Immunovant stock sliding today?
      Sep 23Investing.comIMVT
      Why Is Immunovant Stock Falling Wednesday? - Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT)

      Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.

      Sep 23BenzingaIMVTROIV
      Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows

      Immunovant is discontinuing development of IMVT-1402 in cutaneous lupus but will continue to develop the therapy for several other autoimmune diseases.

      Sep 23Yahoo FinanceIMVT
      Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
      Sep 23Yahoo FinanceIMVTROIV
      Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint

      Immunovant (NASDAQ:IMVT) shares fell 6% on Monday after the company reported that a proof-of-concept study evaluating IMVT-1402 in cutaneous lupus erythematosus did not meet its primary endpoint. The trial did not achieve statistical significance on its primary endpoint, which measured the percentage change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score at Week 12.

      Sep 23Yahoo FinanceIMVT
      Immunovant halts lupus drug development after trial miss
      Sep 23Investing.comIMVT
      Immunovant halts lupus drug trial after missing endpoint
      Sep 23Investing.comIMVT
      Roivant slips on trial setback for Immunovant (ROIV:NASDAQ)
      Sep 23Seeking AlphaIMVTROIV
      Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

      Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140

      Sep 23Yahoo FinanceIMVTROIV
      Immunovant Q1 2027 Earnings Call: Complete Transcript
      Sep 17BenzingaIMVT
      Immunovant (IMVT) Stock Looks Expensive Based On Its Book Value

      Immunovant has delivered very strong long term returns, and that kind of share price journey naturally raises the question of whether the current valuation still lines up with the company’s book value. With fresh attention on its autoimmune drug programs, investors are asking how much of that story is already embedded in the balance sheet metrics. Over the past 5 years, Immunovant has returned 337.4%, which puts a lot of weight on whether the underlying equity on its balance sheet can...

      Sep 15Yahoo FinanceIMVT
      Is Immunovant (IMVT) Undervalued After Its Pullback to $37.36?

      Immunovant (IMVT) has drawn fresh attention after recent trading left the stock around $37.36, with short term moves weaker but a strong total return profile over the past year and beyond. Recent trading tells a mixed story for Immunovant. Short term share price momentum has faded, with the stock down 4.8% over the past week and 10.7% over the past month. However, the 90 day share price return of 11.2% and 1 year total shareholder return of 140.6% show that longer term holders have still seen...

      Sep 14Yahoo FinanceIMVT
      Cantor Fitzgerald reiterates Immunovant stock Overweight rating
      Aug 25Investing.comIMVT
      Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says

      Immunovant (IMVT) has broad diversification with encouraging updates but faces balanced risk/reward

      Aug 24Yahoo FinanceIMVT
      UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating

      Immunovant (IMVT) has an average rating of buy and mean price target of $46.77, according to analyst

      Aug 24Yahoo FinanceIMVT

      This is the newest page. Registered accounts read further back.